IBA

IBA (Ion Beam Applications SA) and Université Catholique de Louvain announced that the first patient treatment with IBA's Proton Therapy Specific Cone Beam CT (CBCT) was successfully completed at Penn Medicine's Roberts Proton Therapy Center.

Ion Beam Applications SA (IBA) announced that the University of Iowa and IBA have signed a research collaboration agreement and a technology license agreement to develop ultra-high precision intensity modulated proton therapy (IMPT). This agreement includes an exclusive license on the Dynamic Collimation System (DCS) recently developed and presented by the University of Iowa at the American Association of Physicists in Medicine (AAPM) meeting in Austin, Texas.

Incidents of cancer are on the rise globally. According to a press release from the World Health Organization’s (WHO) International Agency for Research on Cancer (IARC), “In 2012, the worldwide burden of cancer rose to an estimated 14 million new cases per year, a figure expected to rise to 22 million annually in the next decade.” As the numbers increase around the world, research continues to unveil unconventional options for cancer treatment. Over the past five years, proton therapy has emerged as one popular choice. Hailed by some as the Rolls Royce of radiation oncology, the technology’s precision and accuracy, along with its ability to prevent damage to critical structures and healthy tissues, has made it a technology that many vendors and healthcare facilities are actively investing in.

July 22, 2014 — IBA (Ion Beam Applications SA) announced it has received marketing authorization from the U.S. Food and Drug Administration (FDA) for its compact gantry beam line. IBA anticipates this regulatory approval will intensify the international interest in ProteusONE, IBA’s next-generation proton therapy compact system.